Drugs / Technegas
Technegas
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT04069429 | Jul 2016 → Sep 2020 | eosinophilic esophagitis | University of Utah | Completed | No outcome recorded |
| Phase 32 trials · 1 met primary | ||||||
| Phase 3 | NCT03054870 | Sep 2017 → Sep 2020 | — | Cyclomedica Australia PTY Limited | Terminated | Met primary |
| Phase 3 | NCT01458639 | Aug 2012 → Jun 2015 | pulmonary embolism | Cyclomedica Australia PTY Limited | Terminated | No outcome recorded |
| Comparator or background therapy4 trials | ||||||
| Phase 0 | NCT05859971 Background | Apr → Jun 2023 | breast cancer | University of Wisconsin, Madison | Completed | No outcome recorded |
| Phase 3 | NCT07552597 Comparator | Oct 2026 → Dec 2030 expected | cutaneous melanoma | Vastra Gotaland Region | Not yet recruiting | No outcome recorded |
| — | NCT07146295 Comparator | Apr 2025 → Jul 2026 overdue | breast cancer, metastatic malignant neoplasm in the lymph nodes | Isabelle Henskens | Recruiting | No outcome recorded |
| — | NCT02869308 Background | Jan 2014 → Jan 2018 | — | Central Hospital, Nancy, France | Unknown | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2023-10-05 | Cyclomedica Australia PTY Limited | Regulatory Cyclopharm’s investor presentation: USFDA approval insights cyclomedica.com ↗
On September 29, 2023, Cyclomedica received formal approval from the USFDA, marking a significant achievement in our journey. |
| 2023-10-02 | Cyclomedica Australia PTY Limited | Regulatory United States FDA grants approval for Technegas® cyclomedica.com ↗
Cyclopharm Limited (ASX: CYC) announces the company has received United States Food and Drug Administration (USFDA) approval to commence commercial sales of Technegas in the US market. |
All press releases naming this drug 7 releases
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Technegas | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01458639 ↗ |
| Known as | 99mTc-Technegas | “99mTc-Technegas was recently approved by the U.S. Food and Drug Administration as a radiopharmaceutical for ventilation scintigraphy.” PMID 39638430 ↗ Jan 2025 |
| Known as | Technetium (99mTc) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07146295 ↗ |
| Known as | Technetium Tc 99M | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04069429 ↗ |
| Known as | technetium-99m | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05859971 ↗ |
| Modality | Diagnostic / imaging agent | “99mTc-Technegas was recently approved by the U.S. Food and Drug Administration as a radiopharmaceutical for ventilation scintigraphy.” PMID 39638430 ↗ Jan 2025 |
| Route | Inhaled | “subjects inhaled experimental Technegas” NCT03054870 ↗ |